Heterogeneous uptake of 18F-FDG and 18F-PSMA-1007 PET/CT in lung cancer and lymph node metastasis

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
1 Online-Ressource.
Language
Englisch

Bibliographic citation
Heterogeneous uptake of 18F-FDG and 18F-PSMA-1007 PET/CT in lung cancer and lymph node metastasis ; volume:23 ; number:1 ; day:7 ; month:3 ; year:2023 ; pages:1-5 ; date:12.2023
BMC pulmonary medicine ; 23, Heft 1 (7.3.2023), 1-5, 12.2023

Creator
Hu, Yuan
Wang, Peng
Dai, Wenli
Contributor
SpringerLink (Online service)

DOI
10.1186/s12890-023-02377-9
URN
urn:nbn:de:101:1-2410221330557.240024704558
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:32 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Hu, Yuan
  • Wang, Peng
  • Dai, Wenli
  • SpringerLink (Online service)

Other Objects (12)

Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007

Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007

Preclinical comparative study of [18F]AlF-PSMA-11 and [18F]PSMA-1007 in varying PSMA expressing tumors

Preclinical comparative study of [18F]AlF-PSMA-11 and [18F]PSMA-1007 in varying PSMA expressing tumors

Diagnostic accuracy of [18F]PSMA-1007 PET/CT in biochemical recurrence of prostate cancer

Diagnostic accuracy of [18F]PSMA-1007 PET/CT in biochemical recurrence of prostate cancer

Amelanotic melanoma detected by 18F-FDG PET-CT

Amelanotic melanoma detected by 18F-FDG PET-CT

Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy

Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy

Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy

Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy

Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy

Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy

Optimization of [18F]PSMA-1007 PET-CT using regularized reconstruction in patients with prostate cancer

Optimization of [18F]PSMA-1007 PET-CT using regularized reconstruction in patients with prostate cancer

Diagnostic performance of 18F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer

Diagnostic performance of 18F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer

Isolated Rectal Metastases from Locally Advanced Carcinoma Prostate Detected by 18F-PSMA-1007 PET/CT

Isolated Rectal Metastases from Locally Advanced Carcinoma Prostate Detected by 18F-PSMA-1007 PET/CT

Risk of metastatic disease using [18F]PSMA-1007 PET/CT for primary prostate cancer staging

Risk of metastatic disease using [18F]PSMA-1007 PET/CT for primary prostate cancer staging

[18F]PSMA-1007 PET for biochemical recurrence of prostate cancer, a comparison with [18F]Fluciclovine

[18F]PSMA-1007 PET for biochemical recurrence of prostate cancer, a comparison with [18F]Fluciclovine

Related objects